Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation Journal Article


Authors: Giulino-Roth, L.; Ricafort, R.; Kernan, N. A.; Small, T. N.; Trippett, T. M.; Steinherz, P. G.; Prockop, S. E.; Scaradavou, A.; Chiu, M.; O'Reilly, R. J.; Boulad, F.
Article Title: Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation
Abstract: Background: Autologous or allogeneic hematopoietic stem cell transplant (SCT) is often considered in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) but there are limited data on the use of SCT for the treatment of NHL in the pediatric setting. Procedure: To evaluate the role of SCT for children with NHL, we reviewed 36 consecutive pediatric patients with NHL who underwent an allogeneic (n=21) or autologous (n=15) SCT at our institution between 1982 and 2004. Pathologic classification included: lymphoblastic lymphoma (n=12), Burkitt lymphoma (BL) (n=5), diffuse large B-cell lymphoma (n=4), anaplastic large cell lymphoma (ALCL) (n=13), peripheral T cell lymphoma (n=1), and undifferentiated NHL (n=1). Donor source for allogeneic-SCT recipients was an HLA-matched related donor (n=15), a matched unrelated donor (n=4), or a mismatched donor (related n=1; unrelated n=1). Twenty-eight patients (78%) had chemotherapy responsive disease at the time of transplant (either CR or PR). Results: Overall survival (OS) and disease-free survival (DFS) were 55% and 53% with a median follow-up of 9.75 years. Outcomes were similar in patients receiving autologous and allogeneic-SCT (DFS 53% in both groups). Patients with ALCL had a DFS of 76.9%. In contrast, of five patients transplanted for BL, none survived. DFS among patients with chemotherapy sensitive disease was 61%, compared with 25% among patients with relapsed/refractory disease (P=0.019). Conclusions: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease. Pediatr Blood Cancer 2013;60:2018-2024. © 2013 Wiley Periodicals, Inc.
Keywords: pediatric; autologous stem cell transplant; non-hodgkin lymphoma; allogeneic stem cell transplant
Journal Title: Pediatric Blood and Cancer
Volume: 60
Issue: 12
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2013-12-01
Start Page: 2018
End Page: 2024
Language: English
DOI: 10.1002/pbc.24722
PROVIDER: scopus
PUBMED: 24038967
DOI/URL:
Notes: --- - "Export Date: 1 November 2013" - "CODEN: PBCEA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Nancy Kernan
    435 Kernan
  2. Trudy Small
    215 Small
  3. Farid Boulad
    282 Boulad
  4. Tanya M Trippett
    110 Trippett
  5. Susan E Prockop
    192 Prockop
  6. Lisa B Giulino
    16 Giulino
  7. Peter G Steinherz
    190 Steinherz
  8. Richard O'Reilly
    580 O'Reilly
  9. Michelle Hae-Chung Chiu
    10 Chiu